Schedule M Compliance in 2026: What Updated GMP Rules Mean for Derma Brands
Revised Schedule M compliance has moved from an industry talking point to an active enforcement matter. The Drugs Controller General of India has directed state drug regulators to inspect manufacturing units for compliance, and units that didn't apply for an extension are already subject to this scrutiny.
For a brand that doesn't manufacture in-house, this can feel like someone else's problem. It isn't. The facility making your product carries the direct compliance burden, but the consequences of a facility falling short land on every brand whose name is on that product.
A Rule Most Brand Owners Have Heard of but Not Read
Schedule M sits within the Drugs and Cosmetics Rules, 1945, and sets out the Good Manufacturing Practices that pharmaceutical manufacturers in India must follow, covering everything from facility design to documentation and quality systems.
The revised version was notified in December 2023 and published in the Gazette of India in January 2024, and it represents the most significant overhaul of this framework in decades, built to bring Indian GMP standards closer to WHO-GMP expectations.
The Timeline, in Plain Terms
Large manufacturers were required to comply by January 1, 2025. Micro, small and medium enterprises were given a conditional extension, with an effective compliance date of January 1, 2026, for units that applied for it. As of that date, units that did not apply for an extension are already being inspected under the revised rules, and units that did apply are being scheduled for verification.
The direction from regulators has been consistent: no further extensions are expected, and non-compliance is being treated as a real enforcement matter rather than a formality to catch up on later.
What Actually Changed
A Risk-Based Quality System Instead of a Checklist
The older Schedule M framework worked largely as a checklist of basic requirements. The revised version asks manufacturers to operate a documented Pharmaceutical Quality System that identifies and manages risk across production, rather than simply ticking boxes. This shifts the burden from proving a process was followed to proving that risks were actively identified and controlled.
Stricter Data and Documentation Requirements
Manufacturers are now expected to maintain computerised systems with an audit trail, recording every change made to a record along with who made it and when. This closes a gap that paper-based systems left open, where records could be altered or backdated without a clear trace.
A Broader Shift Toward Demonstrated Compliance
Alongside the quality system and data changes, the general direction of the revision is toward manufacturers demonstrating their standards rather than simply asserting them, whether that's through documentation, testing records or how they respond to an inspection. The exact detail of what's expected varies by product category and is worth confirming directly with a manufacturer or a regulatory consultant rather than assuming a single blanket standard applies everywhere.
Does This Apply to Every Derma Product?
This is where classification matters again, and it's a distinction worth understanding clearly. Schedule M governs products classified as drugs under the Drugs and Cosmetics Act, which includes most therapeutic topical products: antifungal creams, medicated soaps with active ingredients, minoxidil solutions and similar formulations.
Products classified purely as cosmetics fall under a separate framework, the Cosmetics Rules, rather than Schedule M directly. A brand with a mixed range, some drug-classified products and some cosmetic ones, needs to know which of its products actually falls under this compliance requirement rather than assuming the rules apply uniformly across everything it sells.
Why This Matters More Than a Typical Regulatory Update
Regulatory changes happen often enough in pharma that it's easy to treat each one as routine paperwork. This one is different in scale. The shift from a checklist-based system to a risk-based quality system changes how a facility has to think about its entire operation, not just what documents it keeps on file. A facility that previously passed inspection by demonstrating it followed set procedures now needs to show it actively identifies where things could go wrong and has controls in place before problems occur, not just records proving they didn't happen last time.
This distinction sounds technical, but its effect on brands is very practical. A facility that has genuinely adapted its quality culture to this risk-based approach is generally a safer long-term partner than one that has made only the minimum documentation changes needed to pass an inspection. The difference between the two often isn't visible in a single audit, but it shows up over years in how consistently a facility catches problems before they reach a finished batch.
What This Means if You're Not the One Manufacturing
If you work with a third-party manufacturer, you don't carry the manufacturing licence or the direct compliance burden yourself. What you do carry is exposure. If your manufacturer falls short of the revised requirements and faces regulatory action, your supply, your stock and your market presence are all affected, often with very little warning. This is precisely why manufacturer selection has become less about price comparison alone and more about confirming a facility's compliance status directly.
Questions Worth Putting to Your Manufacturer
A few direct questions are worth asking now, not after an inspection notice arrives:
- Has your facility completed its transition to the revised Schedule M requirements, or is it operating under an extension?
- What does your documented quality system actually look like, and can you share an overview of it?
- Do your data systems include an audit trail as required under the revised rules?
- If your facility were inspected tomorrow, what would the outcome be?
A manufacturer who answers these directly, rather than deflecting to a general assurance, is the kind of partner worth staying with through a regulatory transition like this one. If compliance status is part of what you're evaluating, it's worth raising directly with Alister Life Sciences as part of any manufacturing conversation, since this is exactly the kind of question a serious brand should be asking before committing to a partner.
A regulatory transition of this size tends to separate facilities that treat quality as a genuine operating principle from those that treat it as paperwork, and it's worth knowing which one you're working with before your stock depends on it.
Related Articles
- Raw Material Sourcing and QC Testing in Derma Manufacturing
- Exporting Derma Products From India: Documents, Registrations and Target Markets
- Minimum Order Quantity (MOQ) for Third-Party Derma Manufacturing: What Startups Should Expect
